Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

What Rheumatologists Need to Know About the Physician Payment Sunshine Act

Steven M. Harris, Esq.  |  Issue: July 2013  |  July 1, 2013

Steven M. Harris, Esq.
Steven M. Harris, Esq.

In February 2013, the Centers for Medicare and Medicaid Services (CMS) issued the long-awaited Physician Payment Sunshine Act (PPSA) final rule. The PPSA, which was passed as part of the Affordable Care Act in 2010, mandates transparency within physician–industry relationships—namely, the disclosure of physician ownership and investments in healthcare manufacturers and group purchasing organizations (GPOs). Applicable industry manufacturers and GPOs are required to report certain financial relationships with physicians, their immediate family members, and teaching hospitals. These reports are required to be submitted electronically to CMS on an annual basis, with the first report due on March 31, 2014. CMS will post the reported information on a searchable webpage, which will be publicly available.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Who Needs to Report?

Physicians are not required to report their relationships with industry. However, “applicable manufacturers” and “applicable group practice organizations” are required to report financial relationships with physicians and their family members and teaching hospitals. In general, any entity that operates in the United States that is engaged in the production, preparation, compounding, propagation, or conversion of a drug, device, biological, or medical supply available under Medicare or Medicaid has a reporting requirement. Entities under common ownership (direct or indirect ownership of at least 5% by the same person or entity) with a manufacturer and providing “necessary or integral” assistance or support to the manufacturer relating to the product are also covered as manufacturers and have a reporting requirement. The GPO reporting requirements apply to any entity that operates in the United States that purchases, arranges for, or negotiates the purchase of a covered drug, device, biologic, or medical supply for a group of parties, and not solely for itself.

A covered drug, device, biologic, or medical supply is one that requires a prescription to be dispensed or for which the Food and Drug Administration requires premarket approval or notification, and is eligible for payment by Medicare, Medicaid, or Children’s Health Insurance Program.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

What Is Reported?

Manufacturers will be required to annually report direct and indirect payments or other transfers of value to physicians (other than the manufacturer’s bona fide employees) and teaching hospitals. Manufacturers will also need to report any payments or transfers that are made to third parties at the request of or on behalf of a physician or teaching hospital.

In addition, manufacturers and GPOs must report all ownership and investment interests held by physicians or immediate family members of physicians. Required information includes investment amounts, the value and terms of each ownership or investment interest, payments to each physician, and background information regarding each physician investor or owner.

Page: 1 2 3 | Single Page
Share: 

Filed under:Legal UpdatesLegislation & Advocacy Tagged with:LegislationpaymentphysicianRegulationSunshine Act

Related Articles

    President’s Perspective: Will the Physician Payment Sunshine Act Shed Light on Conflicts of Interest?

    July 1, 2013

    What rheumatologists should know about complying with the PPSA when it goes into effect on August 1

    What the Physician Payment Sunshine Act & Open Payments Database Mean in Practice

    January 1, 2015

    Revised CMS policy on payments, transfers of value to physicians incorporates exemption for continuing medical education

    Practice Page: What PQRI Means to Rheumatologists

    November 1, 2010

    The Physician Quality Reporting Initiative (PRQI) is a voluntary quality reporting program initiated by the Centers for Medicare and Medicaid Services (CMS) in 2007. CMS provides bonus payments to eligible providers who successfully report on applicable PQRI measures. For 2010, rheumatologists who successfully participate in PQRI can earn an incentive payment of 2% of the…

    2023 Medicare Physician Fee Schedule Final Rule for Quality Payment Program Published

    January 6, 2023

    The ACR highlights essential policy and reporting changes to the Quality Payment Program for performance year 2023 and beyond. Key changes include policies regarding the development of new MIPS Value Pathways and refinement of subgroup participation.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences